Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology.
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, evaluates a variety of particular systemic treatment agents for possible use in elderly patients.
Dr. David Spigel, Sarah Cannon Cancer Center, outlines treatment options for squamous lung cancer.
It's been over two years since I reported the details from a positive trial for Abraxane (albumin-bound paclitaxel) as a weekly treatment combined with carboplatin and compared with standard "solvent-based" Taxol (paclitaxel) along with carboplatin. While positive for showing a 8% difference in response rate, which was the primary endpoint, it didn't show a significant difference in overall survival (OS), as revealed in the
Three months ago, I discussed the press release from Abraxis reporting that the phase III trial of carbo/Abraxane (nanoparticle albumin-bound paclitaxel) vs. carbo/taxol (paclitaxel) showed a significant benefit for higher response rate in the Abraxane arm. Carboplatin was given one day every three weeks, as was taxol, and Abraxane was given every week (no break).
In addition to developing new agents or refining which patients should or shouldn't be given to particular patients, another way to potentially gain ground in fighting cancer is to improve the tolerability of a standard treatment in a way that either makes it more effective or reduces side effects, thereby making it possible to give higher doses.